c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 128 productos de "c-Met / HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94Vabametkib
CAS:<p>Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.</p>Fórmula:C29H34N12OForma y color:SolidPeso molecular:566.66SOMG-833 HCl
CAS:<p>SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.</p>Fórmula:C22H22F3N5O2Pureza:98%Forma y color:SolidPeso molecular:445.44met-kinase-in-2
CAS:<p>MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.</p>Fórmula:C33H27FN4O4Forma y color:SolidPeso molecular:562.59Entacapone acid
CAS:<p>Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).</p>Fórmula:C10H6N2O6Pureza:98.86%Forma y color:SolidPeso molecular:250.16SOMCL-863
CAS:<p>SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.</p>Fórmula:C23H24F3N5O3Pureza:98%Forma y color:SolidPeso molecular:475.46BPI-9016M
CAS:<p>BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.</p>Fórmula:C25H18F2N4O3Forma y color:SolidPeso molecular:460.43Terevalefim
CAS:<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Fórmula:C9H8N2SPureza:99.8%Forma y color:SolidPeso molecular:176.24c-met-IN-1
CAS:<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Fórmula:C35H37FN6O5Pureza:98%Forma y color:SolidPeso molecular:640.7OSI-296
CAS:<p>OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.</p>Fórmula:C21H19Cl2FN4O3Pureza:98%Forma y color:SolidPeso molecular:465.3MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88Adrixetinib
CAS:<p>Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity .</p>Fórmula:C25H24F3N5O5Forma y color:SolidPeso molecular:531.48Emzeltrectinib
CAS:<p>Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C17H15F3N6OForma y color:SolidPeso molecular:376.34Resencatinib
CAS:<p>Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C30H29N7O3Forma y color:SolidPeso molecular:535.6Tyrosine kinase-IN-6
CAS:<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Fórmula:C37H31F2N5O5SPureza:98%Forma y color:SolidPeso molecular:695.73MK-2461
CAS:<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Fórmula:C24H25N5O5SPureza:95.41% - 99.53%Forma y color:SolidPeso molecular:495.55Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Fórmula:C29H29N9O2Pureza:98.24%Forma y color:SolidPeso molecular:535.6EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02c-Met-IN-2
CAS:<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Fórmula:C24H21FN10OPureza:98%Forma y color:SolidPeso molecular:484.49SJF 8240
CAS:<p>c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.</p>Fórmula:C58H65F2N7O11SForma y color:SolidPeso molecular:1106.25BMS-748730
CAS:<p>BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.</p>Fórmula:C22H26ClN7O3SForma y color:SolidPeso molecular:504.01D6808
<p>D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.</p>Fórmula:C30H25F3N6O2Forma y color:SolidPeso molecular:558.55c-Met-IN-26
CAS:<p>c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.</p>Fórmula:C24H19F2N9Forma y color:SolidPeso molecular:471.46TAM&Met-IN-1
CAS:<p>TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.</p>Fórmula:C29H27F2N7O5Forma y color:SolidPeso molecular:591.57Zurletrectinib
CAS:<p>Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.</p>Fórmula:C19H19F2N7O2Forma y color:SolidPeso molecular:415.4KRC-00715
CAS:<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Fórmula:C25H25F3N8O3Forma y color:SolidPeso molecular:542.51Tyrosine kinase inhibitor
CAS:<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61Canlitinib
CAS:<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Fórmula:C33H31F2N3O7Pureza:98%Forma y color:SolidPeso molecular:619.61
